[2]https://seer.cancer.gov/statfacts/html/breast-subtypes.html[3]Sheffield KM. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022 Jul;18(21):2667-2682.[4]Y. Fan, et al.2023 ESMO abstract 256P.[5] 刘玲玲, 林芳, 韩耀风, 等. 不同分子分型乳腺癌术后复发转移风险及其时间分布规律 [J]. 中国卫生统计, 2017, 34 (01): 7-10+14.[6]Pan H. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017 Nov 9;377(19):1836-1846.[7] 邱鹏飞, 王永胜. 前哨淋巴结时代乳腺癌的精准区域处理: 演进与展望 [J]. 中国癌症杂志, 2022, 32 (08): 680-687.[8]Pagani O. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 Apr 20;38(12):1293-1303.[9]Pedram Razavi, et al.2024 ASC0 e12533.[10]Komal J, et al, 2024 ESMO 292P.